Perfusion-like template and standardized normalization-based brain image analysis using 18F-florbetapir (AV-45/Amyvid) PET

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 6, 2013, Pages 908-920

  Hsiao, Ing Tsung ^a,b,c,e   Huang, Chin Chang ^c   Hsieh, Chia Ju ^a,b   Wey, Shiaw Pyng ^a,b   Kung, Mei Ping ^d   Yen, Tzu Chen ^c   Lin, Kun Ju ^a,b,c  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Department of Medical Imaging and Radiological Sciences ^*  (Taiwan)

Author keywords

Alzheimer's disease; AmyloidPET; Brain template; Dementia

Indexed keywords

AMYLOID PROTEIN; FLORBETAPIR F 18; AMYLOID; ANILINE DERIVATIVE; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR; FLUORINE; DIAGNOSTIC AGENT;

AGED; ALZHEIMER DISEASE; ANTERIOR CINGULATE; ARTICLE; BRAIN PERFUSION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EVALUATION STUDY; FEMALE; FRONTAL LOBE; GRAY MATTER; HUMAN; IMAGE ANALYSIS; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE; OCCIPITAL CORTEX; PARIETAL CORTEX; PERFORMANCE MEASUREMENT SYSTEM; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; TEMPORAL LOBE; BRAIN; CASE CONTROL STUDY; DIAGNOSTIC USE; IMAGE PROCESSING; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PERFUSION; REPRODUCIBILITY; SCINTISCANNING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID; ANILINE COMPOUNDS; BRAIN; CASE-CONTROL STUDIES; ETHYLENE GLYCOLS; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PERFUSION; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS;

EID: 84891709379     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2350-x     Document Type: Article

References (37)

1. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54(11 Suppl 5):S4-9.
2. Rice DP, Fillit HM, Max W, Knopman DS, Lloyd JR, Duttagupta S. Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective. Am J Manag Care 2001;7:809-18.
3. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allg Z Psychiatr Psych-Gerichtl Med 1907;64:146-8.
4. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2- arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003;46:2740-54.
5. Verhoeff NP,Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry 2004;12:584-95.
6. Shoghi-Jadid K, Barrio JR, Kepe V, Wu HM, Small GW, Phelps ME, et al. Imaging beta-amyloid fibrils in Alzheimer's disease: a critical analysis through simulation of amyloid fibril polymerization. Nucl Med Biol 2005;32:337-51.
7. 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008;7:129-35.
8. 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med 2009;50:818-22.
9. 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med 2009;50:1887-94.
10. Lin KJ, Hsu WC, Hsiao IT, Wey SP, Jin LW, Skovronsky D, et al. Whole-body biodistribution and brain PET imaging with [18F]AV- 45, a novel amyloid imaging agent-a pilot study. Nucl Med Biol 2010;37:497-508.
11. Yao CH, Lin KJ, Weng CC, Hsiao IT, Ting YS, Yen TC, et al. GMP-compliant automated synthesis of [(18)F]AV-45 (Florbetapir F 18) for imaging beta-amyloid plaques in human brain. Appl Radiat Isot 2010;68:2293-7.
12. Kung MP, Weng CC, Lin KJ, Hsiao IT, Yen TC, Wey SP. Amyloid plaque imaging from IMPY/SPECT to AV-45/PET. Chang Gung Med J 2012;35:211-8.
13. Vlassenko AG, Mintun MA, Xiong C, Sheline YI, Goate AM, Benzinger TL, et al. Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann Neurol 2011;70:857-61.
14. Raniga P, Bourgeat P, Fripp J, Acosta O, Villemagne VL, Rowe C, et al. Automated (11)C-PiB standardized uptake value ratio. Acad Radiol 2008;15:1376-89.
15. Rosario BL, Weissfeld LA, Laymon CM, Mathis CA, Klunk WE, Berginc MD, et al. Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET. Neuroimage 2011;55:933-41.
16. Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Brück A, et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 2006;67:1575-80.
17. Ashburner J, Friston KJ. Nonlinear spatial normalization using basis functions. Hum Brain Mapp 1999;7:254-66.
18. Meyer JH, Gunn RN, Myers R, Grasby PM. Assessment of spatial normalization of PET ligand images using ligand-specific templates. Neuroimage 1999;9:545-53.
19. Frisoni GB, Lorenzi M, Caroli A, Kemppainen N, Nagren K, Rinne JO. In vivo mapping of amyloid toxicity in Alzheimer disease. Neurology 2009;72:1504-11.
20. 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies. Eur J Nucl Med Mol Imaging 2012;39:613-20.
21. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
22. Association AP. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
23. Joshi A, Koeppe RA, Fessler JA. Reducing between scanner differences in multi-center PET studies. Neuroimage 2009;46:154-9.
24. Mazziotta JC, Toga AW, Evans A, Fox P, Lancaster J. A probabilistic atlas of the human brain: theory and rationale for its development. The International Consortium for Brain Mapping (ICBM). Neuroimage 1995;2:89-101.
25. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002;15:273-89.
26. Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects. J Nucl Med 2012;53:378-84.
27. Yamaguchi H, Hirai S, Morimatsu M, Shoji M, Nakazato Y. Diffuse type of senile plaques in the cerebellum of Alzheimertype dementia demonstrated by beta protein immunostain. Acta Neuropathol 1989;77(3):314-9.
28. Cohen J. The t test for means. In: Cohen J, editor. Statistical power analysis for the behavioural sciences. 2nd ed. Hillsdale: Lawrence Erlbaum Associates; 1988. p. 19-74.
29. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging betaamyloid pathology. JAMA 2011;305:275-83.
30. Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 2003;9:448-52.
31. Braak H, Braak E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol 1991;82:239-59.
32. Fodero-Tavoletti MT, Cappai R, McLean CA, Pike KE, Adlard PA, Cowie T, et al. Amyloid imaging in Alzheimer's disease and other dementias. Brain Imaging Behav 2009;3:246-61.
33. Meyer PT, Hellwig S, Amtage F, Rottenburger C, Sahm U, Reuland P, et al. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B. J Nucl Med 2011;52:393-400.
34. Johnson KA, Albert MS. Perfusion abnormalities in prodromal AD. Neurobiol Aging 2000;21:289-92.
35. Hu WT, Wang Z, Lee VM, Trojanowski JQ, Detre JA, Grossman M. Distinct cerebral perfusion patterns in FTLD and AD. Neurology 2010;75:881-8.
36. Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol 2012;11:669-78.
37. 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging 2012;39:621-31.